Minny/Minny 28 Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing

Concise Prescribing Info

Contents

Desogestrel 0.15 mg, ethinylestradiol 0.02 mg, 7 placebo tab (Minny 28 only)

Indications/Uses

OC.

Click to view Minny/Minny 28 detailed prescribing information

Dosage/Direction for Use

Minny 1 tab daily for 21 days, starting on 1st day of menstruation followed by 7 tab-free days. Minny 28 1 tab daily for 28 consecutive days starting on 1st day of menstruation.

Click to view Minny/Minny 28 detailed prescribing information

Overdosage

View Minny/Minny 28 overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food: Take at about the same time each day.

Contraindications

Hypersensitivity. Thrombophlebitis, thromboembolic disorders (eg, valvular heart disease w/ thrombogenic complications); history of deep vein thrombophlebitis, cerebral vascular disease, MI, CAD. Known or suspected breast & endometrial carcinoma or estrogen-dependent neoplasia. Hepatic adenomas or carcinomas. Undiagnosed abnormal genital bleeding. Uncontrolled HTN. DM w/ vascular complications. Acute liver disease. Cholestatic jaundice of pregnancy or jaundice w/ prior pill use. Known or suspected pregnancy.

Click to view Minny/Minny 28 detailed prescribing information

Warnings

For additional cautionary notes to warn of the potential risk of using the medicine... Click to view Minny/Minny 28 detailed prescribing information

Special Precautions

Do not protect against HIV infections (AIDS) & other sexually transmissible disease. Discontinue if symptoms of thromboembolic & thrombotic disorders are suspected or occur. Increased risk of MI; cerebrovascular events (thrombotic & hemorrhagic strokes) & circulatory disease in women ≥35 yr or w/ other risk factors (eg, smoking, uncontrolled HTN, hypercholesterolemia, obesity, diabetes); cervical intraepithelial neoplasia. Benign & malignant hepatic adenomas; elevated BP & HTN. Avoid smoking. Close clinical surveillance of all women taking OCs & re-exam at least once a yr. Monitor women w/ strong family history of breast cancer or w/ breast nodules & fibrocystic disease, cervical dysplasia, or abnormal mammograms. Consider annual history & physical exam. Pregnancy & lactation.

Click to view Minny/Minny 28 detailed prescribing information

Use In Pregnancy & Lactation

Click to view Minny/Minny 28 detailed prescribing information

Adverse Reactions

Arterial thromboembolism, cerebral hemorrhage, cerebral & coronary thrombosis, gallbladder disease, hepatic adenomas or benign liver tumors, HTN, MI, pulmonary embolism, thrombophlebitis & venous thrombosis w/ or w/o embolism. Dizziness, headache, mental depression, migraine; melasma, rash; breast tenderness, enlargement, & secretion; abdominal cramps, nausea & vomiting, cholestatic jaundice; amenorrhea (during & after treatment), change in cervical secretion, vag candidiasis; contact lens intolerance; edema, reduced carbohydrate tolerance, change in body wt.

Click to view Minny/Minny 28 detailed prescribing information

Drug Interactions

Decreased therapeutic efficacy of anticoagulants. Increased therapeutic effects or toxicity of antidepressants, tricyclics, β-blockers, caffeine, corticosteroids, theophyllines. Increased clearance & prolonged t_½ of benzodiazepines eg, lorazepam, oxazepam, temazepam, alprazolam, chlordiazepoxide, diazepam, triazolam. Decreased pharmacological effect w/ griseofulvin, penicillins or tetracyclines. Decreased effectiveness w/ barbiturates, carbamazepine, hydantoins, phenytoin, rifamycin, St. John's wort.

Click to view Minny/Minny 28 detailed prescribing information

Storage

View Minny/Minny 28 storage conditions for details to ensure optimal shelf-life.

Description

View Minny/Minny 28 description for details of the chemical structure and excipients (inactive components).

Action

View Minny/Minny 28 mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Oral Contraceptives

ATC Classification

G03AA09 - desogestrel and ethinylestradiol ; Belongs to the class of progestogens and estrogens in fixed combinations. Used as systemic contraceptives.

Thai FDA Category

Presentation/Packing

Form

Minny 28 tab

Packing/Price

28's

Form

Minny tab

Packing/Price

21's

Minny/Minny 28

desogestrel + ethinylestradiol

Manufacturer:

Biolab

Distributor:

Biopharm